Pharmafile Logo
Pharmafocus logo
Advanced Search

trial failure

Showing 15 posts of 38 posts found.

shutter

Jazz and PharmaMar’s Zepzelca combo misses main goal in small cell lung cancer sub-population

December 3, 2020
Research and Development PharmaMar, jazz pharma, trial failure

Jazz Pharma and PharmaMar have revealed that their jointly-developed therapy Zepzelca (lurbinectedin), when combined with doxorubicin, fell short of its …

News
roche

Roche’s entrolizumab disappoints at Phase 3 in moderately to severely active ulcerative colitis

August 11, 2020
Manufacturing and Production, Research and Development Roche, etrolizumab, trial failure, ulcerative colitis

Roche has voiced its disappointment after its investigational therapy etrolizumab showed “mixed results” as a treatment for moderately to severely …

News
shutter

Acadia’s pimavanserin falls short at Phase 3 in major depressive disorder

July 21, 2020
Manufacturing and Production, Research and Development Acadia Pharmaceuticals, major depressive disorder, phase 3, trial failure

Acadia Pharmaceuticals has lifted the lid on new Phase 3 for its therapy pimavanserin, revealing that the drug unfortunately failed …

News
merck-keytruda

MSD’s Keytruda misses the mark at Phase 3 in advanced bladder cancer

June 11, 2020
Research and Development MSD< Keytruda, bladder cancer, pharma, trial failure

MSD has announced the disappointing findings that its anti-PD-1 immunotherapy Keytruda (pembrolizumab), when used either alone or combined with chemotherapy, …

News
shutterstock_159488225

Bavencio Phase 3 head and neck cancer trial terminated

March 16, 2020
Research and Development, Sales and Marketing Bavencio, Cancer, EMD Serono, Merck KGaA, Pfizer, trial failure

Merck KGaA, its biopharma division EMD Serono, and Pfizer have announced their decision to terminate their ongoing Phase 3 trial …

News
shutterstock_38078521

AstraZeneca’s cediranib combo misses main goal in platinum-sensitive relapsed ovarian cancer

March 13, 2020
Medical Communications, Research and Development AstraZeneca, cediranib, lynparza, pharma, trial failure

Newly revealed Phase 3 data has shown that AstraZeneca’s oral vascular endothelial growth factor receptor (VEGFR) inhibitor cediranib, when combined …

News
az_logo

Phase 3 failure for AstraZeneca’s Imfinzi combo in unresectable metastatic bladder cancer

March 6, 2020
Medical Communications, Research and Development AstraZeneca, Cancer, Imfinzi, bladder cancer, pharma, trial failure

New Phase 3 has been released by AstraZeneca, showing that the PD-L1 inhibitor Imfinzi (durvalumab), when combined with tremelimumab, failed …

News
lilly_building_with_american_flag_web

Eli Lilly’s solanezumab fails at Phase 2/3 in early-onset Alzheimer’s disease

February 11, 2020
Manufacturing and Production Alzheimer's Eli Lilly, pharma, trial failure

In another blow to Alzheimer’s research, it has emerged that a study investigating Eli Lilly’s solanezumab in the treatment of …

News

Roche’s Tecentriq falls short as an adjuvant monotherapy in muscle-invasive urothelial cancer

January 24, 2020
Medical Communications, Sales and Marketing Cancer, Roche, pharma, tecentriq, trial failure

Roche has released an update on the development of its immunology Tecentriq (atezolizumab), making it known that the drug failed …

News
stock-incyte-01-shutter

Incyte’s drug stumbles at Phase 3 in treatment-naive acute graft-versus-host disease

January 6, 2020
Research and Development, Sales and Marketing Incyte, pharma, trial failure

Drugmaker Incyte has made it known that its selective JAK1 inhibitor therapy itacitinib fell short at Phase 3 in the …

News

Novartis pulls fevipiprant development in asthma following trial failure

December 16, 2019
Research and Development, Sales and Marketing Fevipiprant, Novartis, asthma, pharma, trial failure

Novartis has made it known that its DP2 receptor antagonist fevipiprant failed at Phase 3 to show clinically relevant levels …

News

Biogen terminates gosuranemab in progressive surpanuclear palsy following Phase 2 failure

December 16, 2019
Research and Development, Sales and Marketing Biogen, pharma, trial failure

Biogen has revealed its intention to shut down further development of gosuranemab after results of a Phase 2 study showed …

News
sage_logo

Sage Therapeutics’ depression drug falls short at Phase 3

December 6, 2019
Medical Communications, Research and Development Sage Therapeutics, major depressive disorder, pharma, trial failure

Sage Therapeutics has announced that its candidate SAGE-217 flopped in Phase 3 trials investigating its efficacy in symptom reduction for …

News
shutterstock_243110086

Halozyme culls staff by 55% following Phase 3 metastatic pancreas cancer failure

November 6, 2019
Manufacturing and Production, Research and Development Halozyme, pharma, trial failure

Halozyme Therapeutics has announced it is to cull its workforce by more than half in the wake of the news …

News
index

Catalyst’s lead candidate Firdapse falls short in Congenital Myasthenic Syndromes

October 31, 2019
Research and Development Catalyst Pharmaceuticals, FDA, firdapse, pharma, trial failure

Catalyst Pharmaceuticals has made it known that its lead product Firdapse (Amifampridine Phosphate) fell short of its primary endpoint in …

News

Latest content

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024

AskBio initiates phase 2 Parkinson’s trial recruitment

June 26, 2024

AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment

June 25, 2024

ILiAD Biotechnologies announces collaboration with Emmes Group on phase 3 pertussis vaccine trial

June 25, 2024

GSK’s Jemperli accepted for review by EMA for endometrial cancer treatment

June 24, 2024